

Award Number: DAMD17-01-1-0145

TITLE: Genetic and Functional Studies of Genes that Regulate  
DNA-Damage-induced Cell Death

PRINCIPAL INVESTIGATOR: Zhou Songyang, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine  
Houston, Texas 77030

REPORT DATE: May 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20031106 030

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> May 2003	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 May 02 - 30 Apr 03)	
<b>4. TITLE AND SUBTITLE</b> Genetic and Functional Studies of Genes that Regulate DNA-Damage-induced Cell Death			<b>5. FUNDING NUMBERS</b> DAMD17-01-1-0145	
<b>6. AUTHOR(S)</b> Zhou Songyang, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Baylor College of Medicine Houston, Texas 77030  E-Mail: songyang@bcm.tmc.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b> <p>Studies have shown that apoptosis and survival pathways in response to DNA damage play a critical role in breast cancer development and progression. 90% of breast cancer cases are sporadic where mutations of BRCA1/2 have not been detected. Other breast cancer genes must exist. Our group has approached the issue in two ways, a genomic and a proteomic approach. We have established and utilized a novel retrovirus-based genetic screen system to search for genes that would confer resistance to DNA damage induced apoptosis. Multiple clones have been isolated from this genetic screen. Among the genes identified are both novel and known proteins that may be important in DNA-damage responses. To further elucidate the pathways mediated by BARD1, we looked for factors interacting with BARD1 using mass spec sequencing. Several factors have emerged from this study and are being examined. The information obtained from our studies should prove useful for developing new and effective screening strategies, drug targets, and treatment for breast cancer.</p>				
<b>14. SUBJECT TERMS</b> oncogenes, tumor suppressor, genome-wide, genetic screen, retrovirus, apoptosis, cell survival, BRCA1, BARD1, DNA damage, cancer				<b>15. NUMBER OF PAGES</b> 7
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6
References.....	6
Appendices.....	

## Introduction

Understanding the molecular and cellular mechanisms that trigger breast cancer is essential to the prevention and treatment of this disease. The initiation and progression of breast cancer is likely the result of dysregulation of both oncogenes and tumor suppressor genes (1, 2). Mutations of these genes can cause defects in cellular survival and proliferation, genomic integrity, and sensitivity to DNA damage. However, few genes that regulate DNA damage induced cell death are known to date, and even less is known as to how they interconnect with the apoptosis and survival pathways. We have proposed to establish a genetic system to screen for genes that regulate survival in cultured cells through high-efficiency mutagenesis using Enhanced Retroviral Mutagens (ERM) (3). Due to the random nature of retroviral integration, endogenous genes involved in cell survival signaling cascades may be activated or inactivated by ERM. The targeted gene loci are marked by retroviral integration thereby allowing quick isolation of the candidate genes. The overall objective of this proposal is to identify and study genes that allow the survival of normal and cancerous breast cells. The physiological roles of these genes and their interactions with known signaling pathways will be investigated. Genetic screens will be performed to search for survival genes in response to DNA damage. And the function and signaling mechanisms of BARD1 in breast cancer cell survival will also be examined. The proposed studies should help in our understanding of the molecular basis underlying cell survival signaling and breast cancer as well as provide new therapeutic targets for the cure of this disease.

## Body


For Task 1, we have proposed to isolate mammalian genes involved in breast cancer cell survival. This will be achieved by establishing Enhanced Retrovirus Mutagen (ERM)-mediated genetic screen and analyzing isolated clones, by establishing secondary screens using human breast epithelial cells to confirm the role the cloned genes in DNA-damage-induced apoptosis, and by identifying the candidate genes targeted by ERM

In the last report, we described the employment of a novel retrovirus-based genetic screen system (3) to identify genes that mediate DNA-damage induced apoptosis. Briefly, cytokine-dependent cells were infected with the mutagenesis virus, and selected in the presence of the DNA-damage inducing drug cisplatin (CDDP). Multiple clones have been isolated from this genetic screen. In Table 1, we listed a number of genes that we have identified to date. We are carrying out further studies to clarify the genes that are most relevant to our study.

Genes	Possible function
novel	Conserved through evolution. Binds to RAD50
NESH	Homologue of Abi-1. Sh3 domain containing protein
novel	Unknown function
Lyn	Tyrosine kinase. Involved in DNA-damage response (4-7).

Table 1.

For Task 2, we have proposed to biochemically characterize breast cancer genes including how BARD1 may be involved in breast cancer cell survival. BARD1 was cloned originally as an interactor of BRCA1 and has been implicated as a critical factor in BRCA1 tumor suppression (8). Missense, point mutation and loss-of-function mutations of BARD1 have been found in breast cancers (9). Our preliminary results suggest that BARD1 may modulate cell survival in response to DNA damage. One aspect of the study was to identify the factors that may interact with BARD1. To accomplish this, we took a proteomic approach (Figure 1).



**Figure 1. Flow chart for identification of proteins interacting with BARD1**

Briefly, large amount of human HeLa cells were grown and harvested. Nuclear extracts were made from these cells and then immunoprecipitated in large-scale with an anti-BARD1 antibody. The immunoprecipitates were subsequently resolved by SDS-

PAGE, and visualized by Coomassie Blue Staining. Desired bands were then excised from the gels, digested, and sequenced via Mass Spectrometry.

Through this method, we have identified a number of factors known to interact with BARD1 complexes (Table 2). Furthermore, three novel factors were also identified. And we are actively pursuing these studies.

Genes	Known Function
CPSF-1	multisubunit cleavage and polyadenylation specificity factor (10,1
CPSF-7	multisubunit cleavage and polyadenylation specificity factor (10,1
Symplel	Complexes with BARD1 associated proteins (12).

Table 2.

### Key Research Accomplishments

- Generation of CDDP resistant 32D cell clones
- Establishment of a system to identify BARD1 associated factors
- Successful identification of a number of novel factors from the genetic screen
- Successful identification of a number of novel factors from the proteomic approach

### Reportable Outcomes

We have successfully utilized the ERM approach to identify genes that would confer resistance to CDDP induced cell death. Among the genes identified are both novel and known factors. We have also used a proteomic approach to identify factors in the BARD1 complex. We are currently working on a number of novel proteins in this complex.

### Conclusions

In summary, we have improved and successfully utilized our genetic screen approach for high efficiency mutagenesis. Multiple clones have been isolated and some of the gene loci targeted by the ERM mutagen have also been identified. Furthermore, we are on our way to elucidate how BARD1 may affect cell survival through its interaction with other factors. The information obtained from our studies should prove especially useful for the development of new and effective screening strategies, drug targets, and treatment for breast cancer.

### References

1. Ellisen, L. W., and D. A. Haber. 1998. Hereditary breast cancer. *Annu Rev Med* 49:425-36.
2. Rahman, N., and M. R. Stratton. 1998. The genetics of breast cancer susceptibility. *Annu Rev Genet* 32:95-121.

3. **Liu, D., Yang, X., Yang, D., Songyang, Z.** 2000. Genetic screens in mammalian cells using Enhanced Retroviral Mutagens. *Oncogene* **19**:5964-72.
4. **Yoshida K, Weichselbaum R, Kharbanda S, Kufe D.** 2000. Role for Lyn tyrosine kinase as a regulator of stress-activated protein kinase activity in response to DNA damage. *Mol Cell Biol* **20**:5370-80.
5. **Maruo A, Oishi I, Sada K, Nomi M, Kurosaki T, Minami Y, Yamamura H.** 1999. Protein tyrosine kinase Lyn mediates apoptosis induced by topoisomerase II inhibitors in DT40 cells. *Int Immunol* **11**:1371-80.
6. **Kharbanda S, Saleem A, Yuan ZM, Kraeft S, Weichselbaum R, Chen LB, Kufe D.** 1996. Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2. *Cancer Res* **56**:3617-21.
7. **Kharbanda S, Yuan ZM, Taneja N, Weichselbaum R, Kufe D.** 1994. p56/p53lyn tyrosine kinase activation in mammalian cells treated with mitomycin C. *Oncogene* **9**:3005-11.
8. **Wu, L. C., Z. W. Wang, J. T. Tsan, M. A. Spillman, A. Phung, X. L. Xu, M. C. Yang, L. Y. Hwang, A. M. Bowcock, and R. Baer.** 1996. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. *Nat Genet* **14**:430-40.
9. **Thai, T. H., F. Du, J. T. Tsan, Y. Jin, A. Phung, M. A. Spillman, H. F. Massa, C. Y. Muller, R. Ashfaq, J. M. Mathis, D. S. Miller, B. J. Trask, R. Baer, and A. M. Bowcock.** 1998. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. *Hum Mol Genet* **7**:195-202.
10. **Dichtl B, Blank D, Sadowski M, Hubner W, Weiser S, Keller W.** 2002. Yhh1p/Cft1p directly links poly(A) site recognition and RNA polymerase II transcription termination. *EMBO J* **21**: 4125-35.
11. **Salinas CA, Sinclair DA, O'Hare K, Brock HW.** 1998. Characterization of a Drosophila homologue of the 160-kDa subunit of the cleavage and polyadenylation specificity factor CPSF. *Mol Gen Genet* Apr;257(6):672-80.
12. **Takagaki Y, Manley JL.** 2000. Complex protein interactions within the human polyadenylation machinery identify a novel component. *Mol Cell Biol* **20**:1515-25.